background: the retrieval of good quality oocytes that is accomplished with selection of the best induction ovulation protocol on the basis of patients condition, age and cause of infertility, is one of the most important aspects of art cycles. the objective was to evaluate the efficacy of low dose, long acting gnrh-a (decapeptyle) for pituitary desensitization and outcome of art compared to lo...

GnRH antagonists are safer than agonists: an update of a Cochrane review Background GnRH agonists or antagonists can be used to prevent LH surges during ovarian stimulation for assisted reproduction. GnRH agonists downregulate GnRH pituitary receptors. GnRH antagonists directly and rapidly inhibit gonadotrophin release. In a 2006 systematic review involving 29 trials, the average clinical pregn...

The intended therapeutic effect of gonadotropin-releasing hormone (GnRH) agonists is hypogonadism, a major cause of acquired osteoporosis in men. Consistent with this observation, GnRH agonists increase bone turnover and decrease bone mineral density, a surrogate for fracture risk. Large claims-based analyses and other retrospective studies provide compelling evidence that GnRH agonists increas...

Gonadotropin-releasing hormone (GnRH) receptors are expressed in prostate cancer, specifically in the most aggressive stage of the tumor (castration-resistant prostate cancer, CRPC) for which the standard treatment, docetaxel-based chemotherapy, can only improve the median survival time by few months. We previously showed that GnRH agonists exert an antitumor activity in CRPC cells; however, a ...

BACKGROUND Premature ovarian failure and infertility following chemotherapy are major concerns for premenopausal women with breast cancer. A potential ovarian function preservation strategy is administration of gonadotropin-releasing hormone (GnRH) agonists during adjuvant chemotherapy; however, studies of the clinical efficacy of GnRH agonists to protect chemotherapy-induced ovarian damage hav...

BACKGROUND This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset. METHODS We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received...

J Adv Pract Oncol 2012;3:299–303 Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, as the androgen receptor (AR) plays a role in the development of this malignancy. Androgen-deprivation therapy agents can be classified as gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists. The most common GnRH agents in use are the GnRH agonists. However, these agents...

Gonadotropin-releasing hormone agonists (GnRH agonists) are widely recognised as an effective treatment for patients with moderate to severe symptomatic endometriosis. In addition, the role of GnRH antagonists is being explored. GnRH analogues act by modifying the release of follicle-stimulating hormone (FSH) and luteinising hormone (LH), thereby suppressing ovarian estradiol production. GnRH a...

The crucial role of pituitary GnRH receptors (GnRH-R) in the control of reproductive functions is well established. These receptors are the target of GnRH agonists (through receptor desensitization) and antagonists (through receptor blockade) for the treatment of steroid-dependent pathologies, including hormone-dependent tumors. It has also become increasingly clear that GnRH-R are expressed in...